EUROIMMUN’s IDS i20™ platform represents a major innovation in laboratory automation, offering full automation of chemiluminescence immunoassays (ChLIA) with significantly improved throughput and reagent capacity. As part of Revvity’s diagnostics portfolio, the IDS i20 is both CE-marked and FDA-listed, underscoring its compliance with international standards. The system builds on over five decades of experience in medical device engineering and features a modern software interface, advanced cybersecurity protections, and ergonomic design tailored for today’s high-demand diagnostic labs.

The importance of this launch lies in its ability to unify a wide range of specialty tests on a single platform. Traditionally, many of these diagnostic areas—such as endocrinology, autoimmune disease, and Alzheimer’s testing—have relied on manual or semi-automated methods, limiting scalability and efficiency. The IDS i20 addresses this gap by enabling laboratories to process up to 140 tests per hour while running 20 different analytes across six diagnostic specialties. This leap in versatility and throughput empowers labs to handle growing test volumes without compromising precision or turnaround time.

In practice, the IDS i20 enables continuous operation through its ability to load samples and reagents without stopping the system. Integrated cooling maintains the stability of ready-to-use cartridges, reducing manual intervention and maximizing uptime. As diagnostic demands rise globally, particularly in complex and chronic disease areas, the IDS i20 offers labs a scalable, high-performance solution to transition into fully automated immunodiagnostics. This launch not only strengthens Revvity’s standing in lab automation but also marks a pivotal step toward more efficient, high-capacity clinical testing environments.